CP
Therapeutic Areas
Altis Biosystems Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RepliGut® Planar Model Kits | Pre-clinical Drug Discovery Tool | Commercial Tool |
| RepliGut® Services | Contract Research for Drug Discovery | Service Offering |
| RepliGut® for GI Toxicity Screening | Prediction of Drug-Induced Gastrointestinal Toxicity | Pre-clinical Tool |
| RepliGut® for Intestinal Barrier Function | Assessment of Gut Barrier Integrity | Pre-clinical Tool |
| RepliGut® for Inflammatory Response | Modeling Inflammatory Bowel Disease (IBD) / Inflammation | Pre-clinical Tool |
| RepliGut® for Drug Disposition (DMPK) | Prediction of Oral Drug Absorption & Bioavailability | Pre-clinical Tool |
| RepliGut® for Gut-Brain Axis / GLP-1 Research | Modeling Gut Hormone Release (e.g., GLP-1) & Signaling | Pre-clinical Tool |
Leadership Team at Altis Biosystems
BS
Ben Scruggs, Ph.D.
Chief Executive Officer
MB
Maureen Bunger, Ph.D, M.B.A.
Senior Director of Commercial Strategy
EB
Elizabeth Boazak, PhD
Director of Research & Development
BM
Bryan McQueen, PhD
Senior Scientist II, Manager of Commercial Operations
SP
Swetha Peddibhotla, PhD
Senior Scientist
ET
Earnest Taylor, PhD
Research Scientist II
NB
Napoleon Butler, PhD
Research Scientist II
SB
Stephanie Buchko-Beam
Senior HR Manager
MS
Melanie Sawyer
Senior QA Specialist I
LD
Lauren Di Lella
Senior Research Associate